Show simple item record

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

dc.contributor.authorRuszniewski, Philippe
dc.contributor.authorYao, James
dc.contributor.authorHerrmann, Ken
dc.contributor.authorWild, Damian
dc.contributor.authorVirgolini, Irene
dc.contributor.authorHicks, Rodney J.
dc.contributor.authorKabasakal, Levent
dc.contributor.authorKaltsas, Gregory
dc.contributor.authorLewington, Val
dc.contributor.authorMinozzi, Silvia
dc.contributor.authorCinquini, Michela
dc.contributor.authorOberg, Kjell
dc.contributor.authorOyen, Wim J. G.
dc.contributor.authorO'Toole, Dermot
dc.contributor.authorPavel, Marianne
dc.contributor.authorScarpa, Aldo
dc.contributor.authorTaieb, David
dc.contributor.authorSundin, Anders
dc.contributor.authorStrosberg, Jonathan
dc.contributor.authorAmbrosini, Valentina
dc.contributor.authorKunikowska, Jolanta
dc.contributor.authorBaudin, Eric
dc.contributor.authorBodei, Lisa
dc.contributor.authorBouvier, Catherine
dc.contributor.authorCapdevila, Jaume
dc.contributor.authorCremonesi, Marta
dc.contributor.authorde Herder, Wouter W.
dc.contributor.authorDromain, Clarisse
dc.contributor.authorFalconi, Massimo
dc.contributor.authorFani, Melpomeni
dc.contributor.authorFanti, Stefano
dc.date.accessioned2021-12-10T11:34:48Z
dc.date.available2021-12-10T11:34:48Z
dc.identifier.citationAmbrosini V., Kunikowska J., Baudin E., Bodei L., Bouvier C., Capdevila J., Cremonesi M., de Herder W. W. , Dromain C., Falconi M., et al., "Consensus on molecular imaging and theranostics in neuroendocrine neoplasms", EUROPEAN JOURNAL OF CANCER, cilt.146, ss.56-73, 2021
dc.identifier.issn0959-8049
dc.identifier.otherav_86cea488-3755-4bdc-8aaf-540601248400
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172182
dc.identifier.urihttps://doi.org/10.1016/j.ejca.2021.01.008
dc.description.abstractNuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
dc.language.isoeng
dc.subjectOncology
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectHealth Sciences
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleConsensus on molecular imaging and theranostics in neuroendocrine neoplasms
dc.typeMakale
dc.relation.journalEUROPEAN JOURNAL OF CANCER
dc.contributor.departmentUniversity of Bologna , ,
dc.identifier.volume146
dc.identifier.startpage56
dc.identifier.endpage73
dc.contributor.firstauthorID2607120


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record